Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
Mineralys Therapeutics (Nasdaq: MLYS) announced that its management will participate in the Wells Fargo 21st Annual Healthcare Conference in Boston, held September 8-10, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Mineralys Therapeutics (Nasdaq: MLYS) announced that its management will participate in the Wells Fargo 21st Annual Healthcare Conference in Boston, held September 8-10, 2026. The company is scheduled for a fireside chat on Wednesday, September 9, 2026 at 4:30 p.m. EDT, with a live webcast available via its Investor Relations website.
Details
News Market Reaction – MLYS
On Aug 26, the day this news came out, MLYS closed 1.71% below the previous close.
Data tracked by StockTitan Argus for the Aug 26 session.
Key Figures
- Conference series
- 21st annual
- Wells Fargo Healthcare Conference
- Conference dates
- September 8-10, 2026
- Boston
- Fireside chat date
- September 9, 2026
- Wells Fargo Healthcare Conference
- Fireside chat time
- 4:30pm EDT
- September 9, 2026
Historical Context
-
Equity awards granted to newly appointed Chief Medical Officer Terry Ferguson
-
Quarterly results, lorundrostat update, and revised Tanabe licensing economics
-
Second-quarter results and conference call scheduled for August 11
-
Equity awards granted to newly appointed non-executive employees
-
Management participation in Goldman Sachs healthcare conference fireside chat
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
aldosterone medical
comorbid conditions medical
obstructive sleep apnea medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
RADNOR, Pa., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that management will be participating in the Wells Fargo 21st Annual Healthcare Conference being held in Boston on September 8-10, 2026.
| Wells Fargo 21st Annual Healthcare Conference | |
| Date: | Wednesday, September 9, 2026 |
| Time: | 4:30pm EDT |
| Format: | Fireside Chat |
| Webcast Link: | Click Here |
A live webcast of this fireside chat can also be accessed on the “News & Events” page in the Investor Relations section of the Mineralys Therapeutics website.
About Mineralys Therapeutics
Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, X and Bluesky.
Contact:
Investor Relations
investorrelations@mineralystx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.